A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

BACKGROUND: Targeted agents are standard treatment for RAS wild-type metastatic colorectal cancer in the first- and second-line settings. This phase 2 study determined the benefit of targeting the epidermal growth factor receptor (EGFR) with panitumumab plus irinotecan in irinotecan-refractory patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Elez, Elena, Pericay, Carles, Valladares-Ayerbes, Manuel, Bando, Inmaculada, Safont, Maria Jose, Gallego, Javier, Grávalos, Cristina, Arrivi, Antonio, Carrato, Alfredo, Conde, Verónica, Ortiz, Maria José, López, Carlos, Alonso, Beatriz, Ruiz de Mena, Inmaculada, Díaz-Rubio, Eduardo, Tabernero, Josep, Aranda, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738054/
https://www.ncbi.nlm.nih.gov/pubmed/31363167
http://dx.doi.org/10.1038/s41416-019-0537-z

Ejemplares similares

Ejemplares similares